As of 1:30 PM on the 5th, Pamisell is trading at 22,950 KRW, down 0.86% from the previous day. This represents a 21.75% increase compared to July 9. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Today, foreign investors are tentatively recorded as net sellers of 432,000 shares. Over the past five days, individual investors have net sold 992,088 shares, while foreign and institutional investors have net bought 961,440 shares and 28,498 shares, respectively.
On July 28, Pamisell was a market topic with the news of 'Moderna's Phase 3 clinical trial.'

[Table] Net Trading Volume of Foreign and Institutional Investors (Unit: shares)

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
